Nuvalent
Update in progressNUVL (NGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Nuvalent, Inc. is a Cambridge, Massachusetts‑based clinical‑stage biopharmaceutical company developing targeted cancer therapies. Its lead programs are Zidesamtinib (NVL‑520), a ROS1‑selective inhibitor addressing resistance, CNS toxicities, and brain metastases in ROS1‑positive NSCLC (Phase 2 of ARROS‑1); Neladalkib (NVL‑655), a brain‑penetrant ALK inhibitor for resistance and CNS issues (Phase 2 in ALKOVE‑1); and NVL‑330, a brain‑penetrant HER2 Exon 20–driven therapy (Phase 1a/1b) to avoid wild‑type EGFR inhibition. Established 2017.
Company score
- Sentiment
- 0.54
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.03
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.32
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNGM
- LocationUnited States
- CEODr. James R. Porter Ph.D.
- Founded2017
- Employees234
- Websitenuvalent.com
Identifiers
- ISINUS6707031075
- FIGIBBG00Z1SLMK5
- CUSIP670703107
- CIK0001861560